Abstract
The use of psychostimulants in autistic disorder has not received extensive evaluation. Furthermore, their use for the symptomatic control of autistic disorder has been felt to be contraindicated. This study investigates the use of methylphenidate (MPH) for the treatment of selected symptoms of autistic disorder. Ten children, ages 7–11, with a DSM-III-R diagnosis of autistic disorder participated in a double-blind crossover study using placebo and two MPH doses (10 mg or 20 mg bid). Subjects showed modest but statistically significant improvement on MPH over placebo. No significant side effects including worsening stereotypic movements occurred on either dose. Improvement in hyperactivity and lack of adverse effects suggest that MPH may be useful in the treatment of hyperactive autistic children.
Similar content being viewed by others
References
Aman, M. (1988). The use of methylphenidate in autism [Letter to the editor].Journal of the American Academy of Child and Adolescent Psychiatry, 27, 821–822.
Aman, M., & Singh, N. N. (1985). The Aberrant Behavior Checklist.Psychopharmacological Bulletin, 21, 845–850.
American Psychiatric Association. (1968).Diagnostic and statistical manual of mental disorders (2nd ed.). Washington, DC: Author.
American Psychiatric Association. (1980).Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: Author.
American Psychiatric Association (1987).Diagnostic and statistical manual of mental disorders (3rd ed., rev). Washington, DC: author.
Anderson, L., Campbell, M., Grega, D., et al. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms.American Journal of Psychiatry, 141, 1195–1202.
Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Small, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children.Journal of Autism and Developmental Disorders, 19, 227–239.
Barkley, R. A., DuPaul, G. J., & McMurray, M. B. (1991). Attention deficit disorder with and without hyperactivity: Clinical response to 3 dose levels of methylphenidate.Pediatrics, 87, 519–531.
Birmaher, B., Quintana, H., & Greenhill, L. (1988). Methylphenidate treatment of hyperactive autistic children.Journal of the American Academy of Child and Adolescent Psychiatry, 27, 248–251.
Campbell, M., Adams, P., Perry, R., Spencer, E. K., & Overall, J. E. (1988). Tardive and withdrawal dyskinesia in autistic children: A prospective study.Psychopharmacology Bulletin, 24, 251–255.
Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., & Green, W. H. (1978). A comparison of haloperidol, behavior therapy, and their interactions in autistic children.Journal of the American Academy of Child Psychiatry, 17, 640–655.
Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral Symptoms and Attentional Learning.Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283–1291.
Campbell, M., Anderson, L., Small, A., et al. (1990). Naltrexone in autistic children: A double-blind and placebo controlled study.Psychopharmacological Bulletin, 26, 130–135.
Campbell, M., Fish, B., David, R., Shapiro, T., Collins, P., & Koch, C. (1972). Response to triiodothyronine and dextroamphetamine: A study of preschool, schizophrenic children.Journal of Autism and Childhood Schizophrenia, 2, 343–358.
Campbell, M., Geller, B., & Cohen, I. L. (1977). Current status of drug research and treatment in autistic children.Journal of Pediatric Psychology, 2, 153–161.
Campbell, M., Gonzalez, N. M., Ernst, M., et al. (1993). Neuroleptics. In J. S. Werry & M. G. Aman (Eds.),Practitioners guide to psychoactive drugs for children and adolescents (pp. 269–296). New York: Plenum Press.
Campbell, M., & Green, W. H. (1985). Pervasive developmental disorders of childhood. In H. I. Kaplan & B. J. Sadock (Eds.),Comprehensive textbook of psychiatry (Vol. 4, 4th ed., pp. 1672–1683).
Conners, C. K. (1973). Rating scales for use in drug studies with children. [Special issue]Psychopharmacological Bulletin, 9, 24–42.
Gelfand, R. (1980). Glossary. In H. I. Kaplan, A. M. Freedman, & B. Sadock (Eds.),Comprehensive textbook of psychiatry (Vol. 3, 3rd ed., p. 3334). Baltimore: Williams & Wilkins.
Geller, B., Guttmacher, L., & Bleeg, M. (1981). Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity.American Journal of Psychiatry, 138, 388–389.
Gordon, C. T., State, R. C., Nelson, J. E. et al. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.Archives of General Psychiatry, 50, 441–447.
Goyette, C., Conners, C. K., & Sulrick, R. F. (1978). Normative data on revised Conners parent and teacher ratings scales.Journal of Abnormal Child Psychology, 6, 221–230.
Gualtieri, C. T., Barnhill, J., McGinsey, J., et al. (1980). Tardive dyskinesia and other movement disorders in children treated with psychotropic drugs.Journal of the American Academy of Child Psychiatry, 19, 491–510.
Gualtieri, C. T., Quade, D., Hicks, R. D., et al. (1984). Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents.American Journal of Psychiatry, 141, 20–23.
Guy, W. (1976).ECDEU assessment manual of psychopharmacology. Rockville, MD: NIMH Psychopharmacology Research Branch.
Hoshino, Y., Kumashiro, H., Kanero, M., & Takahashi, Y. (1977). The effects of methylphenidate in early infantile autism and its relation to serum serotonin levels.Folia Psyciatrica et Neurologica Japonica, 31, 605–614.
Keepers, G. A., Clappison, V. J., & Casey, D. E. (1983). Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.Archives of General Psychiatry, 40, 1113–1117.
McDougle, C. L., Price, L. H., Volkmar, F. R. et al. (1992). Clomipramine in autism: Preliminary evidence of efficacy.Journal of Academy of Child and Adolescent Psychiatry, 31, 746–750.
Perry, R., Campbell, M., Adams, P., et al. (1989). A multidimensional long term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration.Journal of American Academy of Child and Adolescent Psychiatry, 28, 87–92.
Perry, R., Campbell, M., Green, W., Small, A., & Trill, M. (1985). Neuroleptic related dyskinesias in autistic children: A prospective study.Psychopharmacology Bulletin, 21, 140–143.
Schopler, E., Reichler, R. J., & Renner, B. (1985). Childhood Autism Rating Scale (CARS).Psychopharmacology Bulletin, 21, 1052–1053.
Schopler, E., Reichler, R. J., & Renner, B. (1988).Childhood Autism Rating Scale (CARS). Los Angeles: Western Psychological Services.
Sloman, L. (1991). Use of medications in pervasive developmental disorders.Psychiatric Clinics of North America, 14, 165–182.
Strayhorn, J. M., Rapp, N., Donina, W., & Strain, P. S. (1988). Randomized trial of methylphenidate for an autistic child.Journal of the American Academy of Child and Adolescent Psychiatry, 27, 244–247.
Vitriol, C., & Farber, B. (1981). Stimulant medication in certain childhood disorders.American Journal of Psychiatry, 138, 1517–1518.
Author information
Authors and Affiliations
Additional information
Formerly at New York State Psychiatric Institute.
Rights and permissions
About this article
Cite this article
Quintana, H., Birmaher, B., Stedge, D. et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25, 283–294 (1995). https://doi.org/10.1007/BF02179289
Issue Date:
DOI: https://doi.org/10.1007/BF02179289